DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162465

Effect of nimodipine and flunarizine on neuromuscular function in mice

Swapnil B. Kaikade, Nitin D. Pise

Abstract


Background: Changes in the intracellular concentration of Ca2+ control a number of cellular and physiological processes, hormone secretion, and cell fate and gene expression. The objective of this study was to study the effect of L-type of calcium channel blocker nimodipine and T-type of calcium channel blocker funarizine on neuromuscular function in mice without pre-treatment by any other drug.

Methods: The study was carried out following permission from the Institutional animal ethics committee. Healthy Swiss albino mice of either sex were selected by the strict inclusion and exclusion criteria and the grouping is done. Group A is control treated with normal saline; group B and C received two titrated doses of nimodipine while group D and E received two titrated doses of flunarizine. The animals were then observed for neuromuscular function and the Statistical analysis was done by using unpaired‘t’ test.

Results: L-type calcium channel blocker nimodipine has dose dependent effect on locomotor activity on traction wire and while the T- type calcium channel blocker flunarizine has no effect on locomotor activity.

Conclusions: Nimodipine has significant dose dependent depressant action on neuromuscular function while flunarizine has no effect on the above mentioned parameter.


Keywords


Nimodipine, Flunarizine, locomotor activity

Full Text:

PDF

References


Mayor S. Diabetes affects nearly 6% of the world’s adults. BMJ. 2006;333:1191.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-31.

Mohan V, Madan Z, Jha R, Deepa R, Pradeepa R. Diabetes-social and economic perspectives in the new millennium. Int J Diab Dev Countries. 2004;24:29-35.

Cantrill JA, Wood J. Diabetes mellitus. In: Walker R, Edwards C, editors. Clinical pharmacology and therapeutic. 3rd ed. New York: Churchill Livingstone; 2003;657-77.

The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.

UK prospective diabetes study group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

Bureau of national health insurance. Drug reimbursement price and date approved by bureau of national health insurance, 2007. Available at http://www.nhi.gov.tw/06inquire/query1.asp. Accessed on 20 June 2007.

Powers AC. Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicines. 15th ed. New York: McGraw- Hill Inc; 2001:2109-37.

Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathological approach. 6th ed. New York: McGraw-Hill Inc; 2005:1333.

Kennedy J, Erb C. Prescription noncompliance due to cost among adults with disabilities in the United States. Am J Public Health 2002;92:1120-4.

Bakssas I, Lunde PKM. National drug policies: the need for drug utilization studies. Trends Pharmacol Sci. 1986;7:331-4.

Press Trust of India. Insulin to cost less. The Hindu; 2003:13:(Col.1).

Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care. 2001;24:1411-5.